Table 3.

Drug‐Resistant mutations after ALK‐TKIs treatment. (?) means the sensitivity of this mutation was not assessed against the given drug; (active) means mutation in that row is inhibited by the addressed drug. The differential colour coding highlights the key residues on the ALK kinase domain, as seen in Fig. 2.

EML4‐ALK kinase inhibitors & drug‐resistant mutations
Crizotinib	Ceritinib	Alectinib	Brigatinib	Lorlatinib
L1196M [46]	?	L1196M	?	?
G1269A [88]	?	?	?	?
C1156Y [45]	C1156Y/T	?	?	?
I1171T/N/S	Active	I1171T/N/S	?	?
S1206 C/Y [ 64 ]	Active	Active	S1206C	?
E1210K [45]	Active	Active	E1210K	?
L1152P/R [46]	L1152P/R	?	?	?
V1180L [88]	Active	V1180L	?	?
I1151T [46, 88]	I1151T	?	?	?
F1174C [89]	F1174C/L	?	?	?
F1245C [90]	Active	?	?	?
G1202R [ 56 ]	G1202R	G1202R	G1202R	?
E1210K [53]	Active	Active	E1210K	?
D1203N [53]	Active	Active	D1203N	?
Active	?	?	?	L1198F [91]
?	?	Active	?	L1256F [92]
?	?	?	?	G1202R/S1206Y [32]